NMS · Financial Statements

Recursion Pharmaceuticals, Inc. (RXRX) Revenue, Earnings & Financial Statements

$2.72 NMS: RXRX Market Cap $1.69B

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Recursion Pharmaceuticals, Inc. most recently reported annual revenue of $75.0M, a net loss of $645.0M. Revenue grew at an average annual rate of 90.4% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Recursion Pharmaceuticals, Inc.: Revenue rose from $2.0M in 2019 to $75.0M in 2025, a change of +3650.0% over 6 years; net profit was positive in 0 of 7 reported years; operating margin moved from -3649.4% to -867.9%, a shift of +2781.5 percentage points; the most recent year shows a net loss of $645.0M.

Income Statement — 7 Years (USD millions)

Metric2019202020212022202320242025
Revenue$2.0M$3.0M$10.0M$40.0M$44.0M$59.0M$75.0M
Operating Expenses$64.0M$88.0M$193.0M$285.0M$394.0M$538.0M$723.0M
Operating Profit−$62.0M−$85.0M−$183.0M−$246.0M−$350.0M−$479.0M−$648.0M
Operating Margin-3649.4%-2479.2%-1827.8%-619.3%-797.8%-814.1%-867.9%
Other Income$1.0M−$2.0M−$4.0M$6.0M$18.0M$14.0M$3.0M
Interest$1.0M$1.0M$3.0M$0$0$2.0M$2.0M
Depreciation$2.0M$4.0M$8.0M$12.0M$24.0M$36.0M$84.0M
Profit Before Tax−$62.0M−$87.0M−$186.0M−$239.0M−$332.0M−$465.0M−$645.0M
Tax rate (%)0.0%0.0%0.0%0.0%1.2%0.2%0.0%
Net Profit−$63.0M−$87.0M−$186.0M−$239.0M−$328.0M−$464.0M−$645.0M
EPS−$0.37−$0.52−$1.05−$1.36−$1.58−$1.69−$1.44

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$11.0M$13.0M$14.0M$26.0M$5.0M$15.0M$19.0M$5.0M$36.0M$6.0M$8.0M$19.0M
Operating Expenses$110.0M$110.0M$115.0M$124.0M$188.0M$206.0M$195.0M$177.0M$144.0M$135.0M$143.0M$142.0M
Operating Profit−$99.0M−$96.0M−$101.0M−$98.0M−$184.0M−$191.0M−$176.0M−$172.0M−$108.0M−$129.0M−$135.0M−$123.0M
Operating Margin-931.2%-714.1%-698.0%-377.1%-4073.8%-1297.8%-922.5%-3327.6%-304.8%-1985.5%-1759.7%-664.0%
Interest$0$0$0$1.0M$1.0M$1.0M$0$1.0M$0$0$0$0
Profit Before Tax−$97.0M−$92.0M−$98.0M−$96.0M−$179.0M−$203.0M−$172.0M−$162.0M−$108.0M−$122.0M−$131.0M−$119.0M
Tax rate (%)4.2%0.8%0.5%-0.2%0.0%0.1%0.0%0.0%-0.0%3.8%0.0%-0.0%
Net Profit−$93.0M−$91.0M−$98.0M−$96.0M−$179.0M−$202.0M−$172.0M−$162.0M−$108.0M−$118.0M−$131.0M−$119.0M
EPS−$0.40−$0.39−$0.40−$0.34−$0.53−$0.50−$0.41−$0.36−$0.21−$0.22−$0.25−$0.22

Over the 7 years reported for Recursion Pharmaceuticals, Inc., borrowings increased from $16.0M in 2019 to $78.0M in 2025, cash stood at $743.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 5.49 times.

Balance Sheet — 7 Years (USD millions)

Metric2019202020212022202320242025
Total Assets$101.0M$299.0M$610.0M$701.0M$654.0M$1.4B$1.5B
Current Assets$76.0M$266.0M$535.0M$570.0M$438.0M$714.0M$813.0M
Cash$70.0M$262.0M$285.0M$550.0M$392.0M$594.0M$743.0M
Inventory$0$0$0$0$0$0$0
Receivables$0$0$9.0M$3.0M$3.0M$49.0M$25.0M
Fixed Assets$24.0M$26.0M$65.0M$121.0M$120.0M$233.0M$169.0M
Capital Work in Progress$0$0$0$0$0$0$0
Investments$0$0$231.0M$0$0$6.0M$0
Other Assets$0$1.0M$1.0M$1.0M$52.0M$149.0M$162.0M
Total Liabilities$226.0M$505.0M$67.0M$215.0M$190.0M$414.0M$343.0M
Current Liabilities$7.0M$23.0M$47.0M$100.0M$93.0M$187.0M$148.0M
Borrowings$16.0M$16.0M$11.0M$51.0M$51.0M$108.0M$78.0M
Other Liabilities$210.0M$489.0M$56.0M$164.0M$140.0M$305.0M$265.0M
Equity$0$0$0$0$0$0$0
Reserves−$124.0M−$206.0M$543.0M$486.0M$463.0M$1.0B$1.1B

For Recursion Pharmaceuticals, Inc., operating cash flow was positive in 0 of 7 reported years; free cash flow in the latest year was negative at $378.0M; free cash flow was positive in 0 of 7 years; financing activities used $3.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 7 Years (USD millions)

Metric2019202020212022202320242025
Operating Cash Flow−$57.0M−$45.0M−$159.0M−$84.0M−$288.0M−$359.0M−$372.0M
Investing Cash Flow−$8.0M−$15.0M−$312.0M$156.0M−$22.0M$246.0M−$23.0M
Financing Cash Flow$0$1.0M$8.0M$11.0M$13.0M$8.0M−$3.0M
Net Cash Flow$59.0M$192.0M$28.0M$264.0M−$158.0M$202.0M$151.0M
Free Cash Flow−$61.0M−$52.0M−$198.0M−$121.0M−$300.0M−$373.0M−$378.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.05
EV / EBITDA-4.24
FCF Yield-14.32%
Quick Ratio5.01
Interest Coverage-751.11
Return 1Y-33.98%
Return 3Y-61.42%
Return 5Y-85.86%

Recursion Pharmaceuticals, Inc. (RXRX) financials — frequently asked questions

What is Recursion Pharmaceuticals, Inc.'s annual revenue?

Recursion Pharmaceuticals, Inc. (RXRX) reported annual revenue of $75.0M in its most recent fiscal year.

What is Recursion Pharmaceuticals, Inc.'s net profit?

Recursion Pharmaceuticals, Inc. (RXRX) reported a net loss of $645.0M in its most recent fiscal year.

What is RXRX EV/EBITDA?

Recursion Pharmaceuticals, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -4.24. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
RXRX Overview RXRX Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.